文献速递神经肿瘤

miR-148a-3p/SIRT7轴促进胶质瘤进展并调控替莫唑胺敏感性

MiR-148a-3p/SIRT7 axis promotes glioma progression and regulates temozolomide chemosensitivity.
PubMed 文献 · J Neurooncol · 2025-10-20

该研究在胶质瘤细胞系中构建SIRT7敲低与过表达模型,结合体内外实验评估SIRT7对胶质瘤进展及替莫唑胺疗效的影响。结果显示SIRT7在胶质瘤患者肿瘤标本中显著高表达,与肿瘤分期及不良预后相关;SIRT7为miR-148a-3p的下游靶点,敲低SIRT7可增强替莫唑胺的细胞毒性与体内抗肿瘤效应。

要点

  • SIRT7在胶质瘤标本中高表达,与肿瘤分期和不良预后相关。
  • miR-148a-3p上调可抑制胶质瘤细胞增殖、阻滞G1期并促进凋亡。
  • 敲低SIRT7可增强替莫唑胺体内外抗胶质瘤效果。

核心结论

  • miR-148a-3p/SIRT7轴驱动胶质瘤进展并调控替莫唑胺敏感性,靶向该轴可能有助于克服耐药。

研究设计与样本

  • 在胶质瘤细胞系中构建SIRT7敲低与过表达模型并检测肿瘤表型。
  • 开展体外与体内实验评估SIRT7表达水平对替莫唑胺治疗效果的影响。

主要发现

  • SIRT7在胶质瘤患者肿瘤标本中显著高表达,且与肿瘤分期及不良预后相关。
  • 降低SIRT7表达可有效阻碍胶质瘤细胞进展。
  • SIRT7被证实为miR-148a-3p的下游靶点。
  • miR-148a-3p上调可抑制胶质瘤细胞增殖、使细胞阻滞于G1期并经凋亡促进细胞死亡。
  • 敲低SIRT7增强替莫唑胺体外细胞毒性,并增强替莫唑胺在胶质母细胞瘤异种移植模型中的抗肿瘤作用。

临床怎么用

  • 该轴为克服胶质瘤替莫唑胺耐药提供潜在干预靶点,尚需进一步临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioma is a highly malignant primary neoplasm of the central nervous system. Temozolomide (TMZ) is the first-line chemotherapeutic drug for glioma, commonly employed in conjunction with radiotherapy to improve overall patient outcomes, but the resistance significantly limits its efficacy. Identifying regulatory molecular targets that influence glioma progression and TMZ sensitivity is critical improve treatment outcomes. Even though SIRT7 has been implicated in tumorigenesis, the regulatory mechanisms of SIRT7 and the role of its upstream microRNAs in glioma progression remain unclear. METHODS: We constructed SIRT7 knockdown and overexpression in glioma cells lines, and detected the tumor phenotypes. Moreover, both in - vitro and in - vivo experiments were carried out to assess the influence of SIRT7 expression levels on the treatment effectiveness of temozolomide (TMZ) in glioma. RESULTS: Our research indicated that SIRT7 is significantly over - expressed in tumor specimens obtained from glioma patients. This over - expression is associated with the tumor stage and a unfavorable prognosis. In addition, reducing the expression of SIRT7 can effectively impede the advancement of glioma cells. It has been confirmed that SIRT7 serves as a downstream target of miR-148a-3p. When there is an upregulation of miR-148a-3p, it suppresses the proliferation of glioma cells. Moreover, it causes tumor cells to become arrested in the G1 phase and stimulates cell death via apoptosis. Interestingly, SIRT7 knockdown enhanced TMZ-induced cytotoxicity in vitro and potentiated TMZ antitumor effects in glioblastoma xenografts. CONCLUSIONS: The aforementioned results suggested the miR-148a-3p/SIRT7 axis drives glioma progression and modulates TMZ sensitivity, and targeting this axis may represent a promising therapeutic approach to overcome TMZ resistance in glioma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Sun K, Wang J, Gao M, et al. MiR-148a-3p/SIRT7 axis promotes glioma progression and regulates temozolomide chemosensitivity. J Neurooncol. 2025. PMID: 41114868. doi:10.1007/s11060-025-05303-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。